Abstract |
This study evaluated the effects of PGA1 on B-16 melanoma-bearing mice. Intraperitoneal injection of PGA1 (10 microgram/day) significantly inhibited the rate of melanoma growth measured both as delay in the rate of appearance and decrease in the tumor volume. In contrast to the diluent control-treated mice, by 17 days, less than half of the PGA1-treated animals developed measurable (greater than 2 mm) subcutaneous tumors. In addition to its effect on tumor size, PGA1 was also effective in stimulating both the humoral and cellular components of the immune response. B-16 tumor-bearing mice were shown to be immunosuppressed, in that they had decreased anti-sRBC hemagglutinin titers, decreased splenic plaque-forming cells, suppressed delayed hypersensitivity responses, and delayed rejection of skin allografts from BALB/c mice. Although, PGA1 had relatively little effect on normal mice, this prostaglandin substantially improved all these immunologic parameters in tumor-bearing animals.
|
Authors | C Favalli, E Garaci, M G Santoro, L Santucci, B M Jaffe |
Journal | Prostaglandins
(Prostaglandins)
Vol. 19
Issue 4
Pg. 587-94
(Apr 1980)
ISSN: 0090-6980 [Print] United States |
PMID | 6992232
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
|
Topics |
- Animals
- Female
- Graft Rejection
(drug effects)
- Immunity
(drug effects)
- Immunity, Cellular
(drug effects)
- Melanoma
(drug therapy, immunology)
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Neoplasms, Experimental
(drug therapy)
- Prostaglandins A
(pharmacology)
- Skin Transplantation
- Transplantation, Homologous
|